MG
NBIX icon

Meditor Group’s Neurocrine Biosciences NBIX Stock Holding History

Meditor Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,050,000
Closed -$11.9M – 19
2013
Q3 		$11.9M Buy
1,050,000
+780,000
+289% +$10.7M 1.68% 23
2013
Q2 		$3.61M Buy
+270,000
New +$3.32M 0.49% 29

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Meditor Group's NBIX Position: Q4 2013 in Review

Meditor Group sold out of Neurocrine Biosciences (NBIX) in Q4 2013, closing a stake of 1,050,000 shares — an estimated $11.9M sold.

Meditor Group first reported a position in NBIX in Q2 2013 and held it in 2 quarters. The position peaked at $11.9M in Q3 2013. 117 funds tracked by Wall St. Rank hold NBIX as of Q4 2013.

  • Meditor Group reported no remaining Neurocrine Biosciences position as of Q4 2013 after selling out during the quarter.
  • Meditor Group sold 1,050,000 Neurocrine Biosciences shares in Q4 2013, an estimated $11.9M.
  • Meditor Group first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 2 quarters.
  • Meditor Group's Neurocrine Biosciences position peaked at $11.9M in Q3 2013.
  • 117 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2013.

Based on Meditor Group's 13F filing for Q4 2013, filed 21 Jan 2014.